



Licensing Opportunity

Monoclonal antibodies against human Chemokine receptor 5 (CCR5)

Scientists at the Georg-August-University Göttingen produced different monoclonal antibodies directed against **phosphorylation sites** of **CCR5**. These antibodies have been demonstrated to exclusively recognise **CD195** phosphorylated at Ser 337 or Ser 349. Human CD195 is a member of the **G protein** coupled superfamily of receptors, which acts as a receptor for a member of chemokines including **RANTES** and also serves as a co-receptor for the entry of **HIV** into cells. It plays a key role in regulating the activation and migration of leukocytes. CD195 is expressed by a subset of T-lymphocytes and by monocytes. Using these antibodies e.g. in combination with our indicator cell line ligand induced phosphorylation or dephosphorylation of CCR5 can be directly measured without using more indirect indicators like **Ca⁺⁺ concentrations**. This principle can be extended to measure activation states of G protein coupled receptors or activity of GPCR kinases generally, e.g. when screening for new agonists, antagonists or GRK inhibitors.

Available Clones for Licensing

Clone	can be used for	results published	Epitope
mouse anti human CCR5 mAb clone E11/19 isotype IgG1-kappa	Immunofluorescence Western Blot ELISA	Pollok-Kopp, B., J. Biol. Chem. 2003, 278: 2190.	Phospho-Ser 349 (GRK-site)
mouse anti human CCR5 mAb clone V14/2 isotype IgG1-kappa	Immunofluorescence Western Blot ELISA	Pollok-Kopp, B., J. Biol. Chem. 2003, 278: 2190.	Phospho-Ser 337 (PKC-site)
mouse anti human CCR5 mAb clone RC-10 isotype IgG1-kappa	Immunofluorescence Western Blot ELISA	Pollok-Kopp, B., J. Biol. Chem. 2003, 278: 2190.	Non-phospho-Ser 337 (PKC-site)
mouse anti human CCR5 mAb clone R22/7 isotype IgG1-kappa	Immunofluorescence Flow Cytometry Western Blot (Immunoprecipitation) (ELISA)	Pollok-Kopp, B., J. Biol. Chem. 2003, 278: 2190.	Ccr5-Aminoterminus (Met1-Lys22)

All hybridoma clones were derived from the fusion of murine splenocytes with X63Ag8.653 myeloma cells and secrete significant amounts of antibodies when grown in 80:20–10 medium (80 parts RPMI 1640, 20 parts medium 199, supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 units/ml), 100 µg/ml streptomycin, hypoxanthine/ thymidine (optional), recombinant human Interleukin-6 (20U/ml)

We are looking for companies, who are interested in **licensing** these antibodies for selling them to industrial and scientific institutions or for developing advanced **diagnostic tests** and **therapeutic solutions**.